Literature DB >> 15912456

[Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].

G B Jaissle1, P Szurman, K U Bartz-Schmidt.   

Abstract

The intravitreal injection as a minimally invasive intervention has proved to be an effective therapy in the management of numerous vitreoretinal diseases. However, non-standardized performance of the procedure might cause severe complications. The recommendations for intravitreal injections discussed here are intended to contribute to a minimization of the risk for complications. Of particular importance are a meticulous preoperative antisepsis with povidone iodine, a sterile environment using a sterile lid speculum, drape and gloves, the use of an adequate injection technique and the exclusion of postoperative retinal non-perfusion.

Entities:  

Mesh:

Year:  2005        PMID: 15912456     DOI: 10.1055/s-2005-858231

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  31 in total

Review 1.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

2.  One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion.

Authors:  Gesine B Jaissle; Martin Leitritz; Faik Gelisken; Focke Ziemssen; Karl Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-12       Impact factor: 3.117

3.  Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Authors:  Kai Januschowski; Nicolas Feltgen; Amelie Pielen; Bernhard Spitzer; Matus Rehak; Georg Spital; Spyridon Dimopoulos; Carsten H Meyer; Gesine B Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

Review 4.  The treatment of wet age-related macular degeneration.

Authors:  Antonia M Joussen; Norbert Bornfeld
Journal:  Dtsch Arztebl Int       Date:  2009-05-01       Impact factor: 5.594

5.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

6.  [Bacterial contamination of needles after intravitreal injection in Paraguay].

Authors:  J C Gines; M M Nentwich; A H Peggy Bedoya; P Cibils; A Esteche; F Laspina; M Samudio; N Fariña; H M de Kaspar
Journal:  Ophthalmologe       Date:  2012-08       Impact factor: 1.059

Review 7.  Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020.

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

Review 8.  [Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity : Released: 18 May 2020].

Authors: 
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

9.  [Intravitreal treatment of patients with branch retinal vein occlusion depending on the duration of macular edema].

Authors:  M Rehak; E Spies; M Scholz; P Wiedemann
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

10.  Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma.

Authors:  Dimitrios Brouzas; Antonios Charakidas; Marilita Moschos; Chryssanthi Koutsandrea; Michael Apostolopoulos; Stefanos Baltatzis
Journal:  Clin Ophthalmol       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.